Clinical Trials Logo
  1. Home
  2. Renal Cancer
  3. NCT00873210
  4. Details
NCT00873210 Clinical Trial

Study In Patients With Kidney Cancer Treated With Sutent

Renal Cancer Clinical Trial

Official title:
Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With Sutent

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00873210
Other study ID # A6181185
Secondary ID
Status Completed
Phase N/A
First received March 30, 2009
Last updated November 7, 2012
Start date May 2009
Est. completion date November 2011

Study information
Verified date November 2012
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority Slovakia: Ethics Commitee of the Bratislava Selgf-Governing Region
Study type Observational

Clinical Trial Summary

Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.

Description:

Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

Recruitment information / eligibility
Status Completed
Enrollment 121
Est. completion date November 2011
Est. primary completion date November 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

Exclusion Criteria:

- Hypersensitivity to sunitinib malate or to any of the excipients

- Any other contraindication to the use of sunitinib malate (based on decision of the treating physician).

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Intervention

Drug:
• Sutent
50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause

Locations
Country Name City State
Slovakia Pfizer Investigational Site Banska Bystrica
Slovakia Pfizer Investigational Site Bojnice
Slovakia Pfizer Investigational Site Bratislava
Slovakia Pfizer Investigational Site Bratislava
Slovakia Pfizer Investigational Site Kosice
Slovakia Pfizer Investigational Site Michalovce
Slovakia Pfizer Investigational Site Nitra
Slovakia Pfizer Investigational Site Poprad
Slovakia Pfizer Investigational Site Presov
Slovakia Pfizer Investigational Site Ruzomberok
Slovakia Pfizer Investigational Site Trebisov
Slovakia Pfizer Investigational Site Trencin
Slovakia Pfizer Investigational Site Trnava
Slovakia Pfizer Investigational Site Zilina

Sponsors (1)
Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

Slovakia, 

Outcome
Type Measure Description Time frame Safety issue
Primary Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib 36 months No
Secondary Dose modifications 36 months No
Secondary Incidence of new diagnosed hypertension 36 months Yes
Secondary Incidence of new diagnosed hypothyroidism 36 months Yes
Secondary Safety of sunitinib malate in "real-life" setting 36 months Yes
Secondary Efficacy of sunitinib malate in "real-life" setting 36 months No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT00531284 - Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma Phase 1/Phase 2
Recruiting NCT05842044 - NSAID Use After Robotic Partial Nephrectomy Phase 2
Recruiting NCT05387863 - Decision Aid (DA) for Renal Patients N/A
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Withdrawn NCT03390413 - Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer N/A
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Active, not recruiting NCT03203473 - Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) Phase 2
Suspended NCT04115254 - Stereotactic Magnetic Resonance Guided Radiation Therapy N/A
Enrolling by invitation NCT02609269 - Decipher Genomics Resource for Intelligent Discovery
Terminated NCT01453595 - BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) Phase 1/Phase 2
Completed NCT01444456 - Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia N/A
Completed NCT02811250 - Stereotactic Radiotherapy for Renal Cancers N/A
Completed NCT00398814 - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers Phase 1
Completed NCT00399152 - Perifosine + Sunitinib Malate for Patients With Advanced Cancers Phase 1
Completed NCT00458536 - Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF Phase 1/Phase 2
Recruiting NCT03693014 - A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors Phase 2
Completed NCT00418496 - Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma Phase 1

External Links